Pharmaceuticals
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...
2026-07-24 09:30
1014
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...
2026-07-24 09:00
732
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...
2026-07-24 08:02
1746
AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...
2026-07-23 22:00
1551
Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has receivedmarketing approval from the National Medical Products Administration of China (NMPA) for t...
2026-07-23 14:08
542
Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice ® transgenic mouse technology platform for translational antibody research CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and de...
2026-07-23 08:55
1610
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...
2026-07-23 08:10
1778
Samsung Biologics Reports Second Quarter 2026 Financial Results
* Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion * Delivered stable business performance through continued disciplined execution * Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026 /PRNe...
2026-07-23 07:03
1946
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...
2026-07-22 21:00
3030
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...
2026-07-22 20:28
3291
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will support completion of IND-enabling activities and planned year-end
IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate
targeting B7-H3-positive solid tumors
SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd.
2026-07-22 19:03
2478
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health. SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene ...
2026-07-22 11:59
1937
China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...
2026-07-22 04:00
2533
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?
T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-...
2026-07-21 20:30
2431
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of...
2026-07-21 19:00
1897
Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations
* The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] * Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against deng...
2026-07-21 16:41
2314
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...
2026-07-21 12:00
1682
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...
2026-07-21 11:50
1949
SuanNutra, Parent Company of Monteloeder and a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF
MADRID, July 20, 2026 /PRNewswire/ -- SuanNutra, the global science-backed ingredients group, today announced it has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE: IFF). The transaction, backed by SuanNutra's majority shareholder Carbyne Equ...
2026-07-21 07:30
5103
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...
2026-07-21 06:52
3651
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 317 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 287 media titles]
2026-07-24 16:25
MetaOptics to Deploy its Direct Laser Writer at the University of Arizona's Center of Semiconductor Manufacturing to Advance its U.S. Expansion
[Picked up by 287 media titles]
2026-07-22 07:30Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
12420